HedgePath Pharmaceuticals to Present at 6th Annual Biotech Showcase Conference

HedgePath Pharmaceuticals to Present at 6th Annual Biotech Showcase Conference

Presentation to be held at Monday, January 13, 2014 at 10:00 a.m. Pacific Time
at the Parc 55 Wyndam in Union Square, San Francisco

PR Newswire

TAMPA, Fla. and SAN DIEGO, Jan. 8, 2014

TAMPA, Fla. and SAN DIEGO, Jan.8, 2014 /PRNewswire/ --HedgePath
Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical
company that discovers, develops and plans to commercialize innovative
therapeutics for patients with cancer, announced today that its president and
chief executive officer, Mr. Nicholas J. Virca, will present at the 6^th
Annual Biotech Showcase Conference to be held in San Francisco, California.
The presentation will occur in the Powell Room on Monday, January 13, 2014 at
10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square.

Mr. Virca will provide an update on HPPI's ongoing plans to repurpose a
patented, specially formulated version of the FDA approved anti-fungal drug
itraconazole (known as SUBA™-Itraconazole) as a cancer inhibitor in Phase II
clinical trials that HPPI intends to launch during 2014. He will also discuss
the drug's potential for commercialization as an oral oncology therapy based
upon previous clinical research undertaken by key investigators in the field
for treatment of lung, skin and prostate cancers.

HPPI has signed an exclusive Supply and License Agreement with a wholly owned
subsidiary of Mayne Pharma Group Limited, whereby HPPI will pursue clinical
development of Mayne Pharma's patented formulation of SUBA-Itraconazole, for
treatment of a variety of cancers with a focus on seeking regulatory approvals
and marketing in the United States.

"SUBA technology" is designed to improve the bioavailability of orally
administered drugs that are poorly soluble. SUBA-Itraconazole was developed
to improve absorption and significantly reduce variability compared to generic
itraconazole. These benefits are designed to provide enhancements to patients
and prescribers with reduced intra- and inter-patient variability, enabling
the potential for a more predictable clinical response and a reduction in the
active drug quantity to deliver the required therapeutic blood levels.

About HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company
that is seeking to repurpose the FDA approved antifungal pharmaceutical
itraconazole as a potential treatment for cancer. HPPI is the exclusive
licensee of a patented formulation of itraconazole, called SUBA-Itraconazole,
which clinical studies have shown to have greater bioavailability than generic
itraconazole.

The Hedgehog signaling pathway is a major regulator of cellular processes in
vertebrates, including cell differentiation, tissue polarity and cell
proliferation. Based on published research, HPPI believes that inhibiting the
Hedgehog pathway could delay or possibly prevent the development of certain
cancers in humans. Leveraging research undertaken by key investigators in the
field, HPPI plans to explore the effectiveness of SUBA-Itraconazole as a
cancer inhibitor and to pursue its potential commercialization. HPPI has
offices in Tampa, Florida and San Diego, California. For more information,
please visit www.hedgepathpharma.com.

Cautionary Note Regarding Forward Looking Statements

This press release, the presentation referred to herein and any statements of
representatives and partners of HedgePath Pharmaceuticals, Inc. (the
"Company") related thereto contain, or may contain, among other things,
certain "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
involve significant risks and uncertainties. Such statements may include,
without limitation, statements with respect to the Company's plans,
objectives, projections, expectations and intentions and other statements
identified by words such as "projects," "may," "will," "could," "would,"
"should," "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "potential" or similar expressions. These statements are based upon
the current beliefs and expectations of the Company's management and are
subject to significant risks and uncertainties, including those detailed in
the Company's filings with the Securities and Exchange Commission. Actual
results (including, without limitation, the outcome of the Company's
collaboration with Mayne and timing for and results of the Company's clinical
trials) may differ significantly from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks and
uncertainties that are subject to change based on various factors (many of
which are beyond the Company's control). The Company undertakes no obligation
to publicly update any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by applicable
law.

For more information:

Company Contact:
HedgePath Pharmaceuticals, Inc., Nicholas J. Virca, President and CEO,
813-864-2559, nvirca@hedgepathpharma.com

Investor Relations Contact:
The Shoreham Group, LLC., Tim Ryan, Managing Director, 212-242-7777,
tryan@shorehamgroupllc.com

© 2014 HedgePath Pharmaceuticals, Inc. All rights reserved.

SOURCE HedgePath Pharmaceuticals, Inc.

Website: http://www.hedgepathpharma.com